Ventilator-associated pneumonia

By M. Valencia, A. Torres. Current Opinion in Critical Care, 2009

2,159 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America (2011, neutral): “Standard protected specimen brush technique through a bronchoscope is not routinely used in ventilated children because it requires a larger bronchoscope, and thus a larger endotracheal tube [180] .”
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. (2007, background): “aeruginosa is the predominant cause of nosocomial pneumonia in ventilated patients [13] and of lung infection in patients with cystic fibrosis [14].”
Health care-associated infections – an overview (2018, background): “[116] [117] [118] [119] [120] [121] A US study found a range of VAP of between 1.2 and 8.5 per 1,000 ventilator days 122 although an international group reported a much higher occurrence of VAP of 13.6/1,000 ventilator days.”
Role of intestinal microbiota and metabolites on gut homeostasis and human diseases (2017, background): “Pseudomonas aeruginosa, an opportunistic pathogen, is a causative agent for diseases like cystic fibrosis, and often accounts for life-threatening nosocomial infections among immunocompromised individuals [82, 83].”